Portal de Periódicos da CAPES

The Role of Basiliximab Induction Therapy in Adult-to-Adult Living-Related Transplantation and Deceased Donor Liver Transplantation: A Comparative Retrospective Analysis of a Single-Center Series

2008; Elsevier BV; Volume: 40; Issue: 6 Linguagem: Inglês

10.1016/j.transproceed.2008.05.062

1873-2623

Jacopo Viganò, Salvatore Gruttadauria, Lucio Mandalà, Ioannis Petridis, Davide Cintorino, Sergio Li Petri, Giovanni Varotti, Marta I. Minervini, Riccardo Volpes, Domenico Biondo, Giovanni Vizzini, Wallis Marsh, A. Marcos, Bruno Gridelli,

Liver Disease and Transplantation

The aim of this study was to report our single-center experience with the use of basiliximab, in combination with a steroid and tacrolimus–based regimen in adult to adult living-related liver transplantation (ALRLT) and in deceased donor liver transplantation (DDLT). Seventy-seven consecutive ALRLT recipients (group 1) and 244 DDLT recipients (group 2) were analyzed. All patients received 2 20-mg doses of basiliximab (days 0 and 4 after transplantation) followed by tacrolimus (0.15 mg/kg/d; 10–15 ng/mL target trough levels) and a dose regimen of steroids. Follow-up ranged from 4–1972 days after transplantation in group 1 and from 1–2741 days in group. In group 1, 89.32% of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.51% within 3 months. Actuarial patient survival rate at 3 years was 84.49%. In group 2, 86.07% of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.04% within 3 months. Actuarial patient survival rate at 3 years was 87.69%. We observed 14 cases of hepatitis C virus (HCV) recurrence in group 1 (prevalence of 26.92%) and 80 cases in group 2 (prevalence of 54.05%). Basiliximab in association with tacrolimus and steroids is effective in reducing episodes of acute cellular rejection (ACR) and increasing ACR-free survival after ALRLT and DDLT. No difference in patient and graft survival was found between group 1 and 2, nor was there any difference in the incidence of ACR between the 2 groups. However, less risk of HCV recurrence was present in the LRLT group.